Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [A264153] Sofpironium is rapidly converted to a less active metabolite, BBI-4010, after exerting its activity, thereby limiting the incidence and/or severity of systemic anticholinergic effects. … Sofpironium is a "soft" anticholinergic analog of [glycopyrronium] that has been modified with a readily hydrolyzable ester moiety.

  2. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    The disorder is associated with recurrent attacks of severe swelling and is thought to be caused by unregulated activity of kallikrein and excessive bradykinin production [FDA Label]. … The amino acid sequence of two compounds differ by seven amino acids [L1458].

    Products: KALBITOR® 10 MG / ML
  3. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas

  4. Drug

    Lutetium Lu177 Edotreotide

    go.drugbank.com/drugs/DB17278
    Investigational

    Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting
  5. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.

  6. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    of total alcohols and not less than 94 percent of straight chain alcohols [L1824]. … Cetyl alcohol is reported to be a mild skin or eye irritant.

    Synonyms: hexadecan-1-ol
  7. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone … and diagnosis of AGHD.

  8. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. … [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060]

    Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled pen
  9. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    The drug is used in the therapy of acute leukemia.

    Synonyms: TG, 6-TGProducts: THIOGUANINE TABLETAS 40 MG, Thioguanin "Aspen" 40 mg Tabletten
  10. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    [A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis. … [A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in